DexCom, Inc. (DXCM)
| Market Cap | 32.96B |
| Revenue (ttm) | 3.95B |
| Net Income (ttm) | 680.80M |
| Shares Out | 390.60M |
| EPS (ttm) | 1.67 |
| PE Ratio | 50.60 |
| Forward PE | 44.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,038,032 |
| Open | 86.32 |
| Previous Close | 84.84 |
| Day's Range | 83.89 - 86.33 |
| 52-Week Range | 62.34 - 142.00 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 99.29 (+17.67%) |
| Earnings Date | Feb 13, 2025 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into t... [Read more]
Financial Performance
In 2023, DexCom's revenue was $3.62 billion, an increase of 24.49% compared to the previous year's $2.91 billion. Earnings were $541.50 million, an increase of 58.70%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for DXCM stock is "Buy." The 12-month stock price forecast is $99.29, which is an increase of 17.67% from the latest price.
News
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued,...
Dexcom forecasts 2025 revenue mostly in-line with expectations
Dexcom forecast total annual revenue in line with Wall Street expectations on Monday, on bets of strong demand for its continuous glucose monitors for diabetes patients.
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook.
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. T...
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health com...
DexCom, Abbott Agree to Settlement in Patent Litigation
The companies have been involved in global patent litigation, with both having accused the other of infringing certain patents, and each has filed counterclaims and actions to invalidate the other par...
Abbott and DexCom settle glucose monitor patent disputes
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
NEW YORK--(BUSINESS WIRE)--EDO, the TV outcomes company, has released its Q3 2024 Diabetes Convergent TV Outcomes Report, providing critical insights into the diabetes category linear and streaming TV...
Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI pla...
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first C...
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) S...
DexCom: Brighter 2025 From Stelo Ramp
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with temporary...
11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs
The S&P is up 27% in 2024, including a 5.5% rally in November. The Euphoria index is at record highs, indicating investor sentiment is extremely bullish. While 2025 is likely to see much larger volati...
DexCom Pairs Its Glucose Monitor With Oura's Smart Ring
If you want to monitor your vital signs like an Olympic athlete, you should welcome a pact between glucose-monitor vendor DexCom and Oura smart rings.
Oura CEO on new partnership with Dexcom
Tom Hale, Oura CEO, joins 'Squawk Box' to discuss the company's new partnership with Dexcom, glucose monitors, and much more.
Smart ring maker Ōura valued at over $5 bln after Dexcom funding
Medical device maker Dexcom said on Tuesday it will invest $75 million in Ōura's latest funding round, valuing the smart ring maker at over $5 billion.
Dexcom and ŌURA Announce Strategic Partnership
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world's leading smart ring, announced today a strategic partners...
Dexcom Helps People With Diabetes Take the First Step to Discover What They're Made Of on World Diabetes Day
SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ste...
3 Top Stocks for Growth Investors to Buy Now
The undervalued stocks of these mid-sized companies with economic moats look attractive.
These Analysts Revise Their Forecasts On DexCom Following Q3 Results
DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday.
DexCom Beats Earnings Expectations. Why the Stock Is Trading Lower.
DexCom's U.S. revenue declines 2% in the third quarter from a year earlier.
Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Friday.
DexCom Growing Into Its Valuation, But Still No Bargain
DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed disa...
DexCom, Inc. (DXCM) Q3 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM) Q3 2024 Earnings Call Transcript October 24, 2024 4:30 PM ET Company Participants Sean Christensen - VP, Finance and IR Kevin Sayer - President and CEO Jereme Sylvain - CFO...